Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9420)
All Articles published online
|
Publishing Process of This Article
|
Aug 14, 2020 (publication date) through May 10, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478 [PMID: 32874058 DOI: 10.3748/wjg.v26.i30.4465] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i30/4465.htm |
| Number | Citing Articles |
| 1 |
Liang Zhang, He Li, TianFu Wang, RuiXin Wang, Long Cheng, Gang Wang. Real-World Study: A Powerful Tool for Malignant Tumor Research in General Surgery. Cancers 2022; 14(21): 5408 doi: 10.3390/cancers14215408
|
| 2 |
Huaiyuan Wang, Ge Zhang, Xiaobo Yang, Zhenhui Lu, Haitao Zhao. Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2023; 1878(1): 188841 doi: 10.1016/j.bbcan.2022.188841
|
| 3 |
Lan Zhang, Junhui Sun, Kui Wang, Haitao Zhao, Xijie Zhang, Zhenggang Ren. First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review. Current Oncology 2022; 29(10): 7305 doi: 10.3390/curroncol29100575
|
| 4 |
Xuefeng Hua, Ziwei Yin, Jin Liang, Wenbin Chen, Hui Gong. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study. European Journal of Gastroenterology & Hepatology 2024; 36(1): 120 doi: 10.1097/MEG.0000000000002668
|
| 5 |
Jincheng Wang, Rui Wu, Jin-yu Sun, Feifei Lei, Huabing Tan, Xiaojie Lu. An overview: Management of patients with advanced hepatocellular carcinoma. BioScience Trends 2022; 16(6): 405 doi: 10.5582/bst.2022.01109
|
| 6 |
Lingbo Hu, Yu Zheng, Jiangyin Lin, Xingpeng Shi, Aidong Wang. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2023; 47(1): 102061 doi: 10.1016/j.clinre.2022.102061
|
| 7 |
Bo Hyun Kim, Su Jong Yu, Wonseok Kang, Sung Bum Cho, Soo Young Park, Seung Up Kim, Do Young Kim. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2022; 37(3): 428 doi: 10.1111/jgh.15727
|
| 8 |
Yuan-Hung Kuo, Sheng-Nan Lu, Yen-Yang Chen, Kwong-Ming Kee, Yi-Hao Yen, Chao-Hung Hung, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang. Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.737767
|
| 9 |
Carla Pires Amaro, Michael J. Allen, Jennifer J. Knox, Erica S. Tsang, Howard J. Lim, Richard M. Lee‐Ying, Kelvin W. Chan, Jessica Qian, Brandon M. Meyers, Alia Thawer, Sulaiman M. S. Al‐Saadi, Tina Hsu, Ravi Ramjeesingh, Hatim Karachiwala, Tasnima Abedin, Vincent C. Tam. Dosing, efficacy and safety of lenvatinb in the real‐world treatment of hepatocellular carcinoma: Results from a Canadian database. Liver Cancer International 2022; 3(3): 119 doi: 10.1002/lci2.59
|
| 10 |
Yuezhi Zhu, Jen Kit Tan, Jo Aan Goon. Cuproptosis- and m6A-Related lncRNAs for Prognosis of Hepatocellular Carcinoma. Biology 2023; 12(8): 1101 doi: 10.3390/biology12081101
|
| 11 |
Yi-Nan Ding, Ming Xue, Qiu-Sha Tang, Li-Jun Wang, Hui-Yan Ding, Han Li, Cheng-Cheng Gao, Wei-Ping Yu. Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges. World Journal of Gastroenterology 2022; 28(37): 5403-5419 doi: 10.3748/wjg.v28.i37.5403
|
| 12 |
Andrea R. Mospan, Heather L. Morris, Michael W. Fried. Real‐world evidence in hepatocellular carcinoma. Liver International 2021; 41(S1): 61 doi: 10.1111/liv.14864
|
| 13 |
Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki. Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals 2021; 14(1): 36 doi: 10.3390/ph14010036
|
| 14 |
Margherita Rimini, Shigeo Shimose, Sara Lonardi, Toshifumi Tada, Gianluca Masi, Hideki Iwamoto, Eleonora Lai, Valentina Burgio, Atsushi Hiraoka, Toru Ishikawa, Caterina Soldà, Tomotake Shirono, Caterina Vivaldi, Koichi Takaguchi, Noritomo Shimada, Giorgio Astara, Hironori Koga, Kazuhiro Nouso, Kouji Joko, Takuji Torimura, Yoichi Hiasa, Francesca Salani, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini. Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study. Hepatology Research 2021; 51(12): 1229 doi: 10.1111/hepr.13718
|
| 15 |
Cuiming Sun, Ying Wen, Jin Zhou. Commentary: Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1372745
|
| 16 |
Mingyue Cai, Wensou Huang, Wei Liang, Yongjian Guo, Licong Liang, Liteng Lin, Lulu Xie, Jingwen Zhou, Ye Chen, Bihui Cao, Jingqiang Wu, Kangshun Zhu. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study. Liver International 2024; 44(4): 920 doi: 10.1111/liv.15831
|
| 17 |
Meng Jia, Jiang-Kun Jia, Jian Xu, Huan-Zhou Xue. Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study. Cancer Management and Research 2022; : 2625 doi: 10.2147/CMAR.S372125
|
| 18 |
I.G. Rapposelli, S. Shimose, T. Kumada, S. Okamura, A. Hiraoka, G.G. Di Costanzo, F. Marra, E. Tamburini, A. Forgione, F.G. Foschi, M. Silletta, S. Lonardi, G. Masi, M. Scartozzi, M. Nakano, H. Shibata, K. Kawata, A. Pellino, C. Vivaldi, E. Lai, A. Takata, K. Tajiri, H. Toyoda, R. Tortora, C. Campani, M.G. Viola, F. Piscaglia, F. Conti, C.A.M. Fulgenzi, G.L. Frassineti, M.D. Rizzato, F. Salani, G. Astara, T. Torimura, M. Atsukawa, T. Tada, V. Burgio, M. Rimini, S. Cascinu, A. Casadei-Gardini. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. ESMO Open 2021; 6(4): 100190 doi: 10.1016/j.esmoop.2021.100190
|
| 19 |
Yuxian Bai, Xichun Hu, Zhenggang Ren, Takashi Hisai, Wataru Yusa, Lidong Weng, Sari Shiba, Takao Takase. A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma. Future Oncology 2022; 18(22): 2413 doi: 10.2217/fon-2022-0229
|
| 20 |
Bo Liu, Xiao Shang, Jin-Yu Shi, Guo-Zhen Cui, Xi Li, Nan-Ya Wang. Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.807189
|
| 21 |
Martina Catalano, Andrea Casadei-Gardini, Gianmarco Vannini, Claudia Campani, Fabio Marra, Enrico Mini, Giandomenico Roviello. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Review of Clinical Pharmacology 2021; 14(11): 1353 doi: 10.1080/17512433.2021.1958674
|
| 22 |
Meng Tao, Jing Han, Juanyi Shi, Hao Liao, Kai Wen, Weidong Wang, Sintim Mui, Huoming Li, Yongcong Yan, Zhiyu Xiao. Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2023; : 1069 doi: 10.2147/JHC.S411806
|
| 23 |
Ming‐Hao Xu, Cheng Huang, Mei‐Ling Li, Xiao‐Dong Zhu, Chang‐Jun Tan, Jian Zhou, Jia Fan, Hui‐Chuan Sun, Ying‐Hao Shen. Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study. Cancer Medicine 2023; 12(8): 9202 doi: 10.1002/cam4.5661
|
| 24 |
Xiaoren Wang, Xudong Cui, Wencan Wang, Jia Sun, Yan Wang, Wanru Han, Xiaotong Xie, Zhu Zhu, Xijun Zhang, Lei Yu, Dabin Liu. Deciphering essential druggable genes reveals potential immune-inflammatory axis in hepatocellular carcinoma. Computers in Biology and Medicine 2023; 167: 107625 doi: 10.1016/j.compbiomed.2023.107625
|
| 25 |
Qingqing Li, Tong Su, Xu Zhang, Yanfeng Pan, Shengli Ma, Lu Zhang, Xianqiang Zhang, Xiaojuan Gao. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma. Cancer Management and Research 2022; : 3037 doi: 10.2147/CMAR.S379911
|
| 26 |
Marie Decraecker, Caroline Toulouse, Jean-Frédéric Blanc. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers 2021; 13(24): 6310 doi: 10.3390/cancers13246310
|
| 27 |
Chihiro Kikugawa, Shinsuke Uchikawa, Tomokazu Kawaoka, Takahiro Kinami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Kenji Yamaoka, Masataka Tsuge, Yumi Kosaka, Kazuki Ohya, Nami Mori, Shintaro Takaki, Keiji Tsuji, Hirotaka Kouno, Hiroshi Kohno, Kei Morio, Takashi Moriya, Michihiro Nonaka, Yasuyuki Aisaka, Keiichi Masaki, Yohji Honda, Noriaki Naeshiro, Akira Hiramatsu, Hiroshi Aikata, Shiro Oka. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab. Oncology 2024; 102(3): 239 doi: 10.1159/000533859
|
| 28 |
Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim. Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis. Journal of Hepato-Biliary-Pancreatic Sciences 2021; 28(12): 1031 doi: 10.1002/jhbp.865
|
| 29 |
Han Ah Lee, Chai Hong Rim. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. Journal of Hepatocellular Carcinoma 2020; : 435 doi: 10.2147/JHC.S285357
|
| 30 |
Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima, Masashi Namikawa, Takashi Ueno, Hiroki Tojima, Daichi Takizawa, Atsushi Naganuma, Hirotaka Arai, Norifumi Harimoto, Ken Shirabe, Toshio Uraoka. Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study. Oncology 2021; 99(10): 641 doi: 10.1159/000517494
|